Tafamidis is primarily used in the treatment of transthyretin amyloidosis, a condition where abnormal protein deposits damage organs and tissues, particularly the heart and nerves. It works by stabilizing the transthyretin protein, preventing its misfolding and the formation of harmful amyloid fibrils. This helps slow the progression of the disease, improving quality of life and reducing symptoms such as neuropathy and heart failure. It is especially beneficial for patients with hereditary or wild-type transthyretin amyloid cardiomyopathy, offering a targeted therapeutic option to manage this rare but serious condition.